SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

PAGANELLI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.319
EU - Europa 3.075
AS - Asia 2.847
SA - Sud America 421
AF - Africa 47
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 5
Totale 16.724
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.279
SG - Singapore 1.382
PL - Polonia 1.267
CN - Cina 755
IT - Italia 420
BR - Brasile 384
TR - Turchia 333
DE - Germania 318
UA - Ucraina 308
SE - Svezia 255
GB - Regno Unito 218
ID - Indonesia 99
VN - Vietnam 88
NL - Olanda 54
HK - Hong Kong 52
IE - Irlanda 48
RU - Federazione Russa 32
AT - Austria 28
CA - Canada 28
JO - Giordania 24
FR - Francia 23
KR - Corea 23
BE - Belgio 22
ZA - Sudafrica 22
FI - Finlandia 17
RO - Romania 14
IN - India 13
AR - Argentina 10
AU - Australia 10
IQ - Iraq 10
PK - Pakistan 8
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
BD - Bangladesh 7
JP - Giappone 7
PT - Portogallo 7
CZ - Repubblica Ceca 6
BO - Bolivia 5
CO - Colombia 5
DZ - Algeria 5
EC - Ecuador 5
GR - Grecia 5
MX - Messico 5
TN - Tunisia 5
BG - Bulgaria 4
DK - Danimarca 4
LT - Lituania 4
MA - Marocco 4
RS - Serbia 4
SC - Seychelles 4
AL - Albania 3
AZ - Azerbaigian 3
CH - Svizzera 3
IR - Iran 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LV - Lettonia 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
SV - El Salvador 3
TW - Taiwan 3
UZ - Uzbekistan 3
CY - Cipro 2
EG - Egitto 2
EU - Europa 2
GA - Gabon 2
GE - Georgia 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
ES - Italia 1
GL - Groenlandia 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
KH - Cambogia 1
LB - Libano 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
TH - Thailandia 1
Totale 16.724
Salva come PNG Salva come JPEG
Città #
Fairfield 1.499
Warsaw 1.263
Woodbridge 1.181
Ashburn 839
Houston 752
Seattle 606
Chandler 551
Santa Clara 538
Jacksonville 495
Wilmington 495
Cambridge 486
Singapore 485
Ann Arbor 380
Izmir 298
Princeton 183
Nanjing 170
Milan 126
San Diego 106
The Dalles 104
Beijing 103
Boardman 101
Jakarta 97
Dearborn 94
Dong Ket 82
Menlo Park 69
Nanchang 67
Los Angeles 66
London 53
Ferrara 52
Hong Kong 48
Hebei 45
Falls Church 42
Shenyang 38
Bologna 33
Council Bluffs 30
Mountain View 30
São Paulo 30
Shanghai 29
Tianjin 29
Changsha 25
Jiaxing 25
Kunming 24
Redwood City 24
Washington 24
Brussels 22
Norwalk 22
Nuremberg 21
New York 19
Orange 19
Rome 19
Scottsdale 16
Jinan 15
Vienna 15
Belo Horizonte 14
Fuzhou 14
Addison 13
Chicago 13
Rio de Janeiro 13
Seongnam 13
Toronto 13
Helsinki 12
Bremen 11
Zhengzhou 11
Tappahannock 10
Guangzhou 9
Indiana 9
Phoenix 9
Brasília 8
Hefei 8
Hounslow 8
Kilburn 8
Poggio Renatico 8
Amsterdam 7
Baghdad 7
Boston 7
Frankfurt am Main 7
Lanzhou 7
Seoul 7
Simi Valley 7
Brooklyn 6
Cesena 6
Changchun 6
Dublin 6
Forlimpopoli 6
North Bergen 6
Porto Alegre 6
Putian 6
Redmond 6
Santo André 6
Tokyo 6
Walnut 6
Amman 5
Buffalo 5
Campinas 5
Castenaso 5
Edinburgh 5
Goiânia 5
Hangzhou 5
La Paz 5
Montreal 5
Totale 12.355
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors 424
Eleven-year experience with the avidin-biotin pretargeting system in glioblastoma: Toxicity, efficacy and survival 304
Use of the FLUKA Monte Carlo code for 3D patient-specific dosimetry on PET-CT and SPECT-CT images 230
Positron emission tomography in the diagnostic work-up of screening-detected lung nodules 225
Development of sentinel node localization and ROLL in breast cancer in Europe 217
Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 212
A new microdispersed albumin derivative potentially useful for radio-guided surgery of occult breast cancer lesions 210
Improper use of "radioguided occult lesion localization" (ROLL) technique leads to misleading conclusions 203
A novel radioguided surgery technique exploiting β- decays 190
Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging 186
18F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide 185
Early use of abiraterone and radium-223 in metastatic prostate cancer 184
Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in mCRPC popUlation for long-teRm Evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice 176
Intramedullary spinal cord metastases from breast cancer: Detection with 18F-FDG PET/CT 170
Local accelerated radionuclide breast irradiation: Avidin-biotin targeting system 166
Atypical primary pulmonary meningioma: A report of a case suspected of being a lung metastasis 166
Peptide receptor radionuclide therapy with 177Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and 18F-FDG PET 163
AvidinOX (TM) for highly efficient tissue-pretargeted radionuclide therapy 152
Radioimmunotherapy in brain tumors 151
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study 144
68 Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients 143
PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis 142
A parathyroid carcinoma within a cold thyroid nodule 141
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas 138
Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors 131
Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: Efficacy profile, safety, and quality of life 131
[18F]FDG positron emission tomography/computed tomography and multidetector computed tomography roles in thymic lesion treatment planning 126
68Ga- DOTA0-Tyr3octreotide (DOTATOC) positron emission tomography (PET)/CT in five cases of ectopic adrenocorticotropin-secreting tumours 124
Role of Positron Emission Tomography Scanning in the Management of Lung Nodules Detected at Baseline Computed Tomography Screening 123
Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status 120
[177 Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet? 120
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors 119
Nuclear medicine in the clinical management (ROLL, SNB, and PET) 119
177Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study 116
Design and solid phase synthesis of new DOTA conjugated (+)-biotin dimers planned to develop molecular weight-tuned avidin oligomers 115
Long-term results of PRRT in advanced bronchopulmonary carcinoid 115
Sentinel lymph node biopsy in pregnant patients with breast cancer 114
Yttrium-labelled peptides for therapy of NET 114
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE 113
Neuroendocrine tumors 113
Intraoperative beta- detecting probe for radio-guided surgery of brain tumors 113
Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors 112
Biotin derivatives carrying two chelating DOTA units. Synthesis, in vitro evaluation of biotinidases resistance, avidin binding, and radiolabeling tests 112
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC 111
Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies 109
Yttrium-based therapy for neuroendocrine tumors 109
Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin) 108
The role of dosimetry in the high activity 90Y-ibritumomab tiuxetan regimens: Two cases of abnormal biodistribution 108
Are we ready for an early evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 107
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: The role of associated risk factors 107
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest 107
OXavidin for tissue targeting biotinylated therapeutics 106
SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes 106
Dosimetry of 177Lu-PSMA-617 after mannitol infusion and glutamate tablet administration: Preliminary results of EUDRACT/RSO 2016-002732-32 IRST protocol 106
68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer 106
Secondary acute myeloid leukaemia after peptide receptor radionuclide therapy 105
Preoperative PET/CT in earlystage breast cancer: Is the TNM classification enough? 105
Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging 104
Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIPradioimmunotherapy in Hodgkin lymphoma patients 104
Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma 104
The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function 104
Hibernoma mimicking metastasis on positron emission tomography-computed tomography imaging: A misleading finding in oncologic patient follow-up 104
Investigation of 90Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I-II clinical study 104
Positron emission tomography for the detection of colorectal adenomas 104
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours 104
Lung cancer screening with low-dose computed tomography: A non-invasive diagnostic protocol for baseline lung nodules 102
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors 102
Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: Results of a phase II study with 90Y-labeled biotin 102
Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin 101
PET imaging of HER-2-positive tumours 101
Therapeutic use of avidin is not hampered by antiavidin antibodies in humans 101
Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3548 cases 101
Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: Preliminary results 101
Investigation of 18F-FDG PET in the selection of patients with breast cancer as candidates for sentinel node biopsy after neoadjuvant therapy 99
Peptide receptor radionuclide therapy in a case of multiple spinal canal and cranial paragangliomas 99
Preoperative FDG PET/CT in breast cancer patients: Where are we going? 99
Is [18F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer? 99
Calculation of electron and isotopes dose point kernels with fluka Monte Carlo code for dosimetry in nuclear medicine therapy 99
Financial aspects of sentinel lymph node biopsy in early breast cancer 99
Treatment of a pituitary metastasis from a neuroendocrine tumour: Case report and literature review 99
The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series 98
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study 97
PET/CT and breast cancer subtypes 97
3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy 97
Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL) 96
Hematologic toxicity and double autografting of stem cells after myeloablative activities of Yttrium-90-Ibritumomab tiuxetan 96
Is a SUV cut-off necessary in the evaluation of the response of axillary lymph node metastases to neoadjuvant therapy? 95
An unusual breast lesion: The ultrasonographic, mammographic, MRI and nuclear medicine findings of mammary hibernoma 95
Sentinel node detection by lymphoscintigraphy and sentinel lymph node biopsy in vulvar melanoma 95
Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone 95
Modification of lymphoscintigraphic sentinel node identification before and after excisional biopsy of primary cutaneous melanoma 94
Radioembolisation with 90Y-microspheres: Dosimetric and radiobiological investigation for multi-cycle treatment 93
Detection of a cardiac mass by [18F]FDG-PET/CT: A rare case 93
Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer 93
Peptide Receptor Radionuclide Therapy (PRRT): clinical Application 92
Nonpalpable breast carcinomas: Long-term evaluation of 1,258 cases 92
Therapeutic schemes in 177Lu and 90Y-PRRT: Radiobiological considerations 91
Development of sentinel node biopsy, ROLL and IART in early breast cancer at the European Institute of Oncology, Milan (IEO) 91
Computed tomography-guided preoperative radiotracer localization of nonpalpable lung nodules 90
Perspectives in the development of novel treatment approaches 90
Totale 12.588
Salva come PNG Salva come JPEG
Categoria #
all - tutte 102.903
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.592
Totale 106.495
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020384 0 0 0 0 0 0 0 0 0 0 274 110
2020/20212.527 106 174 139 228 178 422 132 309 86 315 180 258
2021/20221.303 84 64 35 47 21 133 82 142 69 160 107 359
2022/20231.635 184 44 75 181 195 246 122 151 190 12 148 87
2023/2024881 89 86 64 33 77 131 41 37 22 23 28 250
2024/20253.521 58 97 333 157 510 407 151 253 697 608 250 0
Totale 17.265